We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UBS, Credit Suisse (CS) Might Face Higher Liquidity Requirements
Read MoreHide Full Article
The Swiss regulators are of opinion that both UBS Group (UBS - Free Report) and Credit Suisse Group are required to bolster their liquidity positions. The observation was a result of an analysis conducted on the country’s systemically important banks.
The test results indicated that in case of any emergency or a default event, current liquidity requirements would not be sufficient to weather any downturn.
Per the Banking Act, banks are expected to not require bailing out using taxpayers' money. For this reason, the Federal Council conducts a report every two years to check whether these provisions are in line with the international standards, and how the standards have been implemented abroad.
In this fourth report, the council said that a group with representatives from the Federal Department of Finance (“FDF”), Swiss Financial Market Supervisory Authority and Swiss National Bank has been asked to address how the special, ordinance-level liquidity requirements for systemically important banks might be adjusted.
Also, FDF is expected to present proposals on how incentive systems for systemically important banks could be better anchored in terms of global resolvability.
Following the collapse of Archegos Capital Management in March, both the above mentioned banks were affected majorly.
Losing $5.5 billion, Credit Suisse became the bank that took the biggest hit among its peers. In fact, the loss wiped out almost all of its profits made in the first quarter of 2021. If it had not incurred the Archegos loss, Credit Suisse could have reported one of its best quarterly financial performances in almost a decade.
Banks like Credit Suisse, Nomura (NMR - Free Report) , Morgan Stanley, UBS Group, Mitsubishi UFJ Financial Group (MUFG - Free Report) and Mizuho Bank were the prime brokers that offered almost $50 billion worth of leverage to Archegos but collectively lost more than $10 billion due to the fallout.
Shares of UBS Group and Credit Suisse have gained 37.8% and 2.1%, respectively, over the past six months compared with 41% growth of the industry it belongs to.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
UBS, Credit Suisse (CS) Might Face Higher Liquidity Requirements
The Swiss regulators are of opinion that both UBS Group (UBS - Free Report) and Credit Suisse Group are required to bolster their liquidity positions. The observation was a result of an analysis conducted on the country’s systemically important banks.
The test results indicated that in case of any emergency or a default event, current liquidity requirements would not be sufficient to weather any downturn.
Per the Banking Act, banks are expected to not require bailing out using taxpayers' money. For this reason, the Federal Council conducts a report every two years to check whether these provisions are in line with the international standards, and how the standards have been implemented abroad.
In this fourth report, the council said that a group with representatives from the Federal Department of Finance (“FDF”), Swiss Financial Market Supervisory Authority and Swiss National Bank has been asked to address how the special, ordinance-level liquidity requirements for systemically important banks might be adjusted.
Also, FDF is expected to present proposals on how incentive systems for systemically important banks could be better anchored in terms of global resolvability.
Following the collapse of Archegos Capital Management in March, both the above mentioned banks were affected majorly.
Losing $5.5 billion, Credit Suisse became the bank that took the biggest hit among its peers. In fact, the loss wiped out almost all of its profits made in the first quarter of 2021. If it had not incurred the Archegos loss, Credit Suisse could have reported one of its best quarterly financial performances in almost a decade.
Banks like Credit Suisse, Nomura (NMR - Free Report) , Morgan Stanley, UBS Group, Mitsubishi UFJ Financial Group (MUFG - Free Report) and Mizuho Bank were the prime brokers that offered almost $50 billion worth of leverage to Archegos but collectively lost more than $10 billion due to the fallout.
Shares of UBS Group and Credit Suisse have gained 37.8% and 2.1%, respectively, over the past six months compared with 41% growth of the industry it belongs to.
One-Year Price Performance
Both the stocks are currently carrying a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>